Found: 8
Select item for more details and to access through your institution.
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL1.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 8, p. 1196, doi. 10.1002/ajh.26949
- By:
- Publication type:
- Article
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. 1560, doi. 10.1002/ajh.26724
- By:
- Publication type:
- Article
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD‐negative remission.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. E408, doi. 10.1002/ajh.26698
- By:
- Publication type:
- Article
Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. E201, doi. 10.1002/ajh.26526
- By:
- Publication type:
- Article
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
- Published in:
- Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01476-8
- By:
- Publication type:
- Article
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01229-z
- By:
- Publication type:
- Article
Liquid biopsies and minimal residual disease in lymphoid malignancies.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1173701
- By:
- Publication type:
- Article
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
- Published in:
- Acta Haematologica, 2022, v. 145, n. 5, p. 529, doi. 10.1159/000525566
- By:
- Publication type:
- Article